Verrica Pharmaceuticals Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative treatments for skin diseases. Founded in 2018, Verrica has quickly established itself in the dermatology sector, particularly in the treatment of conditions such as molluscum contagiosum. The company’s flagship product, VP-102, is a unique topical therapy that utilises a proprietary formulation to effectively target viral skin infections. This innovative approach sets Verrica apart in a competitive market, positioning it as a key player in dermatological therapeutics. With a commitment to advancing patient care, Verrica Pharmaceuticals continues to make significant strides in the industry, aiming to improve the quality of life for those affected by challenging skin conditions.
How does Verrica Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Verrica Pharmaceuticals Inc.'s score of 23 is lower than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Verrica Pharmaceuticals Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Verrica Pharmaceuticals may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the pharmaceutical industry increasingly prioritises sustainability, it will be essential for Verrica to consider developing and communicating its climate commitments to align with industry standards and expectations.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Verrica Pharmaceuticals Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
